500-mg vs 1000-mg Ceftriaxone for Uncomplicated Gonorrhea
Official title: 500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection: A Noninferiority Randomized Controlled Trial
Run by National Taiwan University Hospital · NCT07710118 · Data updated 2026-11-12
This study tests whether a 500-mg dose of ceftriaxone works as well as a 1000-mg dose for treating uncomplicated gonorrhea in men.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 400 (estimated) |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | July 2026 |
| Main results expected | December 2028 |
| Study ends | June 2029 |
| Registry record updated | July 17, 2026 |
| Trial ID | NCT07710118 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men 18 years and older with confirmed uncomplicated gonorrhea at oropharyngeal, anorectal, or urogenital sites.
✕Probably not a fit
Patients with complicated gonorrhea, co-infections requiring different therapy, or ceftriaxone allergy may not benefit from the tested doses.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 3 noninferiority randomized trial comparing two ceftriaxone doses for uncomplicated gonorrhea in men. Participants are adults with oropharyngeal, anal, or urogenital gonorrhea confirmed by culture or a positive NAAT. The study aims to determine if the lower dose achieves similar cure rates to the higher dose while avoiding unnecessary higher-dose exposure. Exclusions include complicated gonorrhea, recent systemic antibiotic use, and co-infection with certain pathogens or ceftriaxone allergy. The trial is conducted at multiple centers in Taiwan and is sponsored by National Taiwan University Hospital with several collaborating sites.
Why it matters
Potential benefit: If successful, the lower ceftriaxone dose could reduce drug exposure and potential side effects while maintaining effectiveness.
How similar studies have gone: Noninferiority trials comparing antibiotic dosing for gonorrhea have shown mixed results; this study addresses a specific dosing comparison in uncomplicated cases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older man, and * having oropharyngeal, anorectal or urogenital N. gonorrhoeae infection confirmed by culture or a positive NAAT Exclusion Criteria: * Suspicion of a complicated N. gonorrhoeae infection. Complicated N. gonorrhoeae infection is defined as the presence of epididymitis, arthritis, bacteremia, conjunctivitis, or disseminated gonococcal infection. * Use of systemic cephalosporins, doxycycline, or azithromycin at the screening visit or within 30 days prior to the enrollment visit is prohibited. Participants who require immediate antibiotic treatment at the screening visit, based on clinician judgment or shared decision-making with the participant, without awaiting PCR or culture confirmation, will be excluded from the study. Use of doxycycline for post-exposure prophylaxis (Doxy-PEP) is permitted. * A NAAT test positive for C. trachomatis or M. genitalium at the screening visit. * A history of allergy or intolerance to ceftriaxone, penicillins, or lidocaine, in alignment with the contraindications listed in the Sintrix (ceftriaxone) injection package insert. Allergy or intolerance is defined as the occurrence of adverse symptoms following antibiotic administration, including but not limited to skin rash, pruritus, dyspnea, angioedema, anaphylaxis, dizziness, nausea, vomiting, headache, or diarrhea. Laboratory abnormalities include cytopenias, eosinophilia, and elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or creatinine. Penicillins include natural penicillins (e.g., penicillin G), aminopenicillins (e.g., amoxicillin, ampicillin), penicillinase-resistant penicillins (e.g., oxacillin, dicloxacillin), extended-spectrum penicillins (e.g., piperacillin), and other agents classified within the penicillin class.
Where it's running
-
National Taiwan University Hospital
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Tzong-Yow Wu, M.D.
- Email: retep0102@gmail.com
- Phone: 886+933594074
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
iStatis gonorrhea antigen test — accuracy, ease of use, and result reading
This tests whether the iStatis point-of-care gonorrhea antigen test gives accurate results and is easy for trained staff to use in people older than 16 who need STI testing.
-
AI-assisted home-based mood diary for kids with ADHD
A home-based program uses an AI-assisted diary that turns daily mood entries into comic strips to see if it helps kids with ADHD improve emotion regulation.
-
Probiotic supplement BRCAS-C3 and its effect on androgen levels
This pilot study tests whether taking Bacillus coagulans BRCAS-C3 daily for 24 weeks can safely lower or alter androgen levels in healthy adults.
-
Biomarkers that predict medication-related side effects in children with ADHD
This study tests whether combined brain, cognitive, and metabolite markers can predict side effects from methylphenidate in kids with ADHD.
-
Daily-life Virtual Reality Training to Support Thinking and Daily Tasks in adults 50 and older
A touchscreen-based daily-life VR program is being tested to see if it helps people 50+ improve daily activities and thinking skills, especially for those at risk of dementia.
-
Pompe disease long-term monitoring with avalglucosidase alfa
This is an observational program to see how people with Pompe disease who started avalglucosidase alfa fare over time, including biomarkers, muscle and breathing function, and safety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.